ObsEva SA – SIX:OBSN.SW
ObsEva SA stock price today
ObsEva SA stock price monthly change
ObsEva SA stock price quarterly change
ObsEva SA stock price yearly change
ObsEva SA key metrics
Market Cap | 140.61K |
Enterprise value | 8.45M |
P/E | -0.31 |
EV/Sales | N/A |
EV/EBITDA | -0.14 |
Price/Sales | N/A |
Price/Book | -2.66 |
PEG ratio | -0.01 |
EPS | 0.09 |
Revenue | N/A |
EBITDA | 1.34M |
Income | 7.92M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeObsEva SA stock price history
ObsEva SA stock forecast
ObsEva SA financial statements
| Sep 2022 | 3.70M | -12.05M | -325.07% |
|---|---|---|---|
| Dec 2022 | 19.63M | 26.77M | 136.36% |
| Mar 2023 | 0 | -3.39M | |
| Jun 2023 | 0 | -3.39M |
| Sep 2022 | 16807000 | 19.95M | 118.74% |
|---|---|---|---|
| Dec 2022 | 16544000 | 8.06M | 48.72% |
| Mar 2023 | 9022000 | 5.91M | 65.55% |
| Jun 2023 | 9022000 | 5.91M | 65.55% |
| Sep 2022 | -5.09M | 0 | -30.34M |
|---|---|---|---|
| Dec 2022 | 7.92M | -5.67M | 2.50M |
| Mar 2023 | -2.43M | 3.26M | -3.35M |
| Jun 2023 | -2.43M | 3.26M | -3.35M |
ObsEva SA alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 15 |
| Nov 2023 | 15 |
| Dec 2023 | 15 |
| Jan 2024 | 15 |
| Feb 2024 | 15 |
| Mar 2024 | 15 |
| Apr 2024 | 15 |
| May 2024 | 15 |
| Jun 2024 | 15 |
| Jul 2024 | 15 |
ObsEva SA other data
| Insider | Compensation |
|---|---|
Mr. Brian O'Callaghan (1969) Chief Executive Officer & Director | $4,290,000 |
Dr. Ernest Loumaye (1952) Co-Founder & Director | $1,000,000 |
-
What's the price of ObsEva SA stock today?
One share of ObsEva SA stock can currently be purchased for approximately $1.99.
-
When is ObsEva SA's next earnings date?
Unfortunately, ObsEva SA's (OBSN.SW) next earnings date is currently unknown.
-
Does ObsEva SA pay dividends?
No, ObsEva SA does not pay dividends.
-
How much money does ObsEva SA make?
ObsEva SA has a market capitalization of 140.61K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11.55% to 19.64M US dollars.
-
What is ObsEva SA's stock symbol?
ObsEva SA is traded on the SIX under the ticker symbol "OBSN.SW".
-
What is ObsEva SA's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ObsEva SA?
Shares of ObsEva SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ObsEva SA's key executives?
ObsEva SA's management team includes the following people:
- Mr. Brian O'Callaghan Chief Executive Officer & Director(age: 56, pay: $4,290,000)
- Dr. Ernest Loumaye Co-Founder & Director(age: 73, pay: $1,000,000)
-
Is ObsEva SA founder-led company?
Yes, ObsEva SA is a company led by its founder Dr. Ernest Loumaye.
-
How many employees does ObsEva SA have?
As Jul 2024, ObsEva SA employs 15 workers.
-
When ObsEva SA went public?
ObsEva SA is publicly traded company for more then 7 years since IPO on 13 Jul 2018.
-
What is ObsEva SA's official website?
The official website for ObsEva SA is obseva.com.
-
How can i contact ObsEva SA?
ObsEva SA can be reached via phone at +41 22 552 38 40.
ObsEva SA company profile:
ObsEva SA
obseva.comSIX
15
Biotechnology
Healthcare
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Geneva, 1228
:
ISIN: CH1260041939
:
